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Interleukin 17A (IL-17)-producing CD4þ T helper type 17 (Th17) cells have recently drawn attention as
possible effector cells of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell trans-
plantation (HCT) in murine models. Their role after allogeneic HCT in humans is unknown. In this prospective
study, Th17, Th1/17, and Th1 cells were quantiﬁed in the peripheral blood of 80 patients within the ﬁrst
3 months after allogeneic HCT using intracellular cytokine staining and ﬂow cytometry. Within the obser-
vation period, Th1, Th1/17, and Th17 cells did not reconstitute to levels of healthy control subjects. In contrast
to Th1 cells, no further expansion of Th1/17 and Th17 cells was observed during the ﬁrst month after HCT.
Antithymocyte globulin during conditioning signiﬁcantly reduced the frequency of Th1/17 and Th17 cells but
not of Th1 cells. Acute GVHD was not associated with signiﬁcant changes in the size of the Th1, Th1/17, or
Th17 cell subsets. Cytomegalovirus reactivation triggered the expansion of all T helper subsets, and Th1 cells
showed the strongest increase. In contrast, no signiﬁcant changes were found in the T helper cell compart-
ment of patients with bacterial infections compared with time-matched control subjects. In conclusion,
quantitative reconstitution of Th1, Th1/17, and Th17 cells is impaired within the ﬁrst 3 months after HCT,
especially when antithymocyte globulin is administered during conditioning. Cytomegalovirus reactivation,
but not acute GVHD or bacterial infection, triggered the absolute expansion of these T cell subsets.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION GVHD [12,13]. In another murine model, the absence of Th17
Allogeneic hematopoietic cell transplantation (HCT) is
a curative treatment option for hematologic diseases [1]. One
major risk for patients after donor cell engraftment is acute
graft-versus-host disease (GVHD) [2]. Donor Tcells have been
demonstrated to be the primary immune cells to induce
GVHD, as their depletion ex vivo or in vivo (eg, using antith-
ymocyte globulin [ATG]) lowered the incidence of acute
GVHD in rodents and humans [2-4]. After activation, allor-
eactive donor-derived naive CD4þ T cells differentiate into
distinct lineages of effector T helper cells expressing unique
sets of transcriptional factors and cytokines. Acute GVHD has
been classically assumed to bemediated by T helper cells type
1 (Th1), characterized by the production of interferon-g (IFN-
g). This paradigm has been questioned, because acute GVHD
has also been shown tobe induced inmice by IFN-gedeﬁcient
or Stat4-deﬁcient Tcells, indicating that Tcells other thanTh1
are capable of mediating allo-reactivity as well [5,6].
The recent discovery of interleukin-17A (IL-17)-producing
T helper type 17 (Th17) cells and their proinﬂammatory
functions in autoimmune diseases [7,8] led to the hypothesis
that these cells could also contribute to GVHD. Th17 cells
were shown in mouse models either to augment GVHD [9-
11] or to independently induce liver, gut, lung, and skinedgments on page 365.
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12.11.018cells led to augmented Th1 differentiation and exacerbation
of acute GVHD, indicating that GVHD can occur indepen-
dently of Th17 cells [14]. Yu et al. recently demonstrated that
targeting both Th1 and Th17 transcription factors T-bet and
RORgt successfully ameliorated GVHD while preserving
graft-versus-leukemia effects [15]. Despite these lines of
evidence in patients, conﬂicting results were obtained on the
role of Th17 cells in acute GVHD [16-20]. It was discovered
that a subpopulation of human Th17 cells coexpress IFN-g
and IL-17 (so-called Th1/17 cells) and that human Th17 cells
are susceptible for Th1 differentiation and therefore could
contribute to Th1 immune responses in vivo [21-23].
We hypothesized that IFN-g/IL-17 production and quan-
tity of T helper cells might depend on the time after HCT,
immune responses to alloantigens (acute GVHD) or patho-
gens (eg, bacterial infection, cytomegalovirus [CMV] reac-
tivation), and the presence of T celledepleting antibodies (eg,
ATG). To explore this hypothesis, we initiated the ﬁrst
prospective study to investigate the reconstitution of Th1,
Th1/17, and Th17 cells in patients after allogeneic HCT and
asked whether altered proportions of these T helper cells are
correlated with (1) acute GVHD, (2) CMV reactivation, (3)
bacterial infection, or (4) ATG in the conditioning regimen.
METHODS
Study Population
Eighty patients with various hematologic disorders undergoing alloge-
neic human leukocyte antigen (HLA)-matched HCT at our center between
December 2009 and September 2010 were included in the study (Table 1).Transplantation.
Table 1
Patient Characteristics
Median Range
Age, yr 56 19-74
n Percent
Total 80 100
Male 42 52.5
Diagnosis
Acute myeloid leukemia 28 35
Acute lymphatic leukemia 12 15
Myelodysplastic syndrome 10 12.5
Chronic lymphatic leukemia 9 11.25
Non-Hodgkin lymphoma 12 13.75
Multiple myeloma 4 5
Primary myeloﬁbrosis 3 3.75
Chronic myelomonocytic leukemia 1 1.25
Aplastic anemia 1 1.25
Hodgkin disease 1 1.25
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whereas 65 patients received grafts from unrelated donors. Blood samples
were collected in consecutive patients once in early engraftment (ﬁrst
month,<31 days after HCT), in the secondmonth after HCT (days 31-60 after
HCT), and during late engraftment (61-110 days after HCT). Eight healthy
age-matched donors were included as control subjects. Blood samples of all
subjects were collected after obtaining written informed consent.
The study was approved by the institutional review board of the Dres-
den Medical Faculty. Exclusion criteria for the study were (1) death before
engraftment, (2) viral reactivation other than CMV (human herpes virus 6,
adenovirus, Epstein-Barr virus, Polyomavirus BK), (3) aspergillus or other
fungal infection treated with granulocyte infusions, (4) HLA-haploidentical
transplantation, (5) age younger than 18 years, (6) graft failure, (7) use of
alemtuzumab in the conditioning regimen, or (7) relapse of acute myelog-
enous leukemia within 110 days post-HCT.
Patients received either myeloablative conditioning (MAC, 26.25%) or
reduced-intensity conditioning (RIC, 73.75%) before graft infusion (Table 2).
All patients received granulocyte colony-stimulating factoremobilized
grafts from HLA-matched related or unrelated donors (CD34þ cells/kg;
median, 8.0  106; range, 1.36  106 to 1.11  107). After graft infusion,
patients received for GVHD prophylaxis either cyclosporine (n ¼ 10) or
combinations of cyclosporine withmethotrexate (n¼ 54), cyclosporine with
mycophenolate mofetil (n ¼ 7), tacrolimus with methotrexate (n ¼ 7), or
tacrolimus with mycophenolate mofetil (n ¼ 2).Table 2
Conditioning Regimen
n Percent
Myeloablative (no ATG) 16 20
Bu16/Cy 9 11.25
Flu/Bu16 6 7.5
12GyTBI/Eto 1 1.25
Myeloablative þ ATG 5 6.25
Flu/Bu16 þ ATG 2 2.5
12GyTBI/Eto þ ATG 2 2.5
Bu16/Cy þ ATG 1 1.25
Reduced intensity (no ATG) 44 55
Flu/Bu8 24 30
Flu/Mel 7 8.75
Flu/2-8GyTBI þ/ Thio 7 8.75
Flu/Treo 4 5
Flu/Bu10 2 2.5
Reduced intensity þ ATG 15 18.75
Flu/2-8GyTBI þ/ Thio þ ATG 5 6.25
Flu/Mel þ ATG 4 5
Flu/Bu10 þ ATG 3 3.75
Flu/Treo þ ATG 2 2.5
Flu/Bu8 þ ATG 1 1.25
ATG indicates ATG Fresenius (20 mg/kg/d) for 3 days; Bu, busulfan, Bu8
(8 mg/kg p.o. total), Bu10 (10 mg/kg p.o. total), Bu16 (16 mg/kg p.o. or
12.5 mg/kg i.v. total); Cy, cyclophophamide (110-120 mg/kg total);
Eto, etoposide (45-60 mg/kg total); Flu, ﬂudarabine (30 mg/m2/d for 3-6
days); Mel, melphalane (140 mg/m2 total); TBI, fractionated total body
irradiation (2, 8, or 12 Gy); Thio, thiotepa (10 mg/kg total); Treo, treosulfan
(14 g/m2/d for 3 days)For each time period (ﬁrst month, second month, and late engraftment),
patient cohorts were deﬁned according to the following criteria:
1. Bacterial infection: All patients were monitored daily for clinical signs
of infection and the C-reactive protein level in the peripheral blood.
Bacterial infection was deﬁned by the presence of a C-reactive protein
level >50 mg/L in the peripheral blood, together with positive blood
culture or fever in the absence of a viral or fungal infection.
2. CMV reactivation: Patients were monitored for CMV reactivation twice
weekly using CMV-speciﬁc polymerase chain reaction in the peripheral
blood. In case of increasing viral load (>400 genome copies per mL),
patients were pre-emptively treated with ganciclovir. Blood samples
were collected before treatment with ganciclovir.
3. Acute GVHD: The presence of acute GVHD was classiﬁed according to
the Seattle criteria. Blood samples were collected before the applica-
tion of high-dose prednisolone (1 to 2 mg/kg).
4. ATG: Patients receiving ATG as GVHD prophylaxis in the conditioning
regimen were infused with ATG (Fresenius, Biotech GmbH, Gräfelﬁng,
Germany) at a dose of 20 mg/kg on day 3, 2, and 1 before HCT.
As a reference group, we chose time-matched and age-matched patients
that did notmeet any of the criteria under investigation (absence of bacterial
infection, CMV reactivation, acute GVHD, ATG, or prednisolone). Patients
who fulﬁlled simultaneously more than one criterion were excluded from
any analysis to avoid confounding.
Monoclonal Antibodies
The following ﬂuorochrome-labeled monoclonal antibodies were used
to perform cell surface staining: allophycocyanin-labeled anti-CD3 (HIT3a,
IgG2ak) and peridinin-chlorophyll-protein complexelabeled anti-CD4 (SK3,
IgG1k; both from BD Biosciences, San Jose, CA). For intracellular cytokine
staining, phycoerythrin-labeled antieIL-17 (eBio64CAP17, IgG1k; from
eBioscience, San Diego, CA) and ﬂuorescein-isothiocyanateelabeled
antieIFN-g (4S.B3, IgG1k; from BD Biosciences) were used. Phycoerythrin-
labeled mouse IgG1k (MOPC-21, IgG1k; BD Bioscience) and ﬂuorescein-
isothiocyanateelabeled mouse IgG1, k (MOPC-21, IgG1k; BD Bioscience)
served as isotype controls and were used in equal concentrations.
Preparation, Stimulation, and Staining of Peripheral Blood
Mononuclear Cells
Lymphocyte counts in the peripheral blood were determined using
a Sysmex XE-5000 Hematology Analyzer (Sysmex Deutschland GmbH, Nor-
derstedt, Germany). For subsequent FACS analysis, peripheral blood mono-
nuclear cells (PBMCs)were selected fromperipheral blood by centrifugation,
using a Ficoll (Biochrom,Berlin, Germany) gradientbycentrifugation at 980
g for 15 minutes. PBMCs were adjusted to an absolute concentration of 106/
mL in RPMI 1640 medium supplemented with 10% heat-inactivated human
serum blood type AB (c-c-pro, Oberdorla, Germany), 2- mM L-alanyl-L-
glutamine, and 1% sodium-pyruvate/nonessential amino acids/penicillin-
streptomycin (all from Biochrom AG, Berlin, Germany).
For analysis of surface phenotype and intracellular cytokine staining,
PBMCs were seeded into 24-well culture plates (Greiner Bio-One GmbH,
Frinkenhausen, Germany) in 1- mL RPMI 1640 medium (with supplements,
see above) and 106 cells per well, stimulated with phorbol myristate acetate
(10 ng/mL) and ionomycin (1 mg/mL; both from Sigma-Aldrich, St. Louis,
MO), and cultivated for 5 hours at 37C in a 5% CO2 incubator. Golgistopper
brefeldin (1 mg/mL, Sigma) was added at the beginning of stimulation. After
5 hours, cultivation cells were stained for surface antigens for 15 minutes at
4C. After surface staining, cells were ﬁxed using 4% paraformaldehyde
(Merck Chemicals, Darmstadt, Germany) at 4C for 15 minutes and per-
meabilized using 0.01% saponin-solution (Merck Chemicals) at 4C for 3
minutes. After permeabilization, cells were stained for intracellular cyto-
kines for 15minutes at 4C. Finally, cells werewashed 3 times with cell wash
(phosphate-buffered saline from Biochrom AG supplemented with 0.05%
Azid NaN3 from Sigma).
Flow Cytometry
Flow cytometry was performed using a FACSCalibur cytometer and
CellQuest Pro software for data analysis (Becton Dickinson, San Jose, CA).
CD3þCD4þ T helper cells were detected in the lymphocyte gate. CD3þCD4 T
cells were not further analyzed. The percentage of Th1 (IFN-gþIL-17), Th17
(IFN-gIL-17þ), Th1/17 (IFN-gþIL-17þ), and non-Th1/17 (IFN-gIL-17) cells
was determined according to their cytokine production of IFN-g and IL-17
(Figure 1A). Isotype controls yielded no signiﬁcant staining. Absolute cell
numbers were calculated using the following formula: % gated of total
lymphocytes  total lymphocyte counts (as determined using the
Sysmex XE-5000 Hematology Analyzer). Cell quantities are indicated as
gigaparticles per liter (GPt/L ¼ 1  109 cells/L), megaparticles per liter
(MPt/L ¼ 1  106 cells/L), or kiloparticles per liter (KPt/L ¼ 1  103 cells/L).
Figure 1. (A) Quantiﬁcation of IFN-ge and IL-17Aeproducing T helper cells using ﬂow cytometry. Gating of IFN-gIL-17 (non-Th1/17), IFN-gþIL-17 (Th1), IFN-gþIL-
17þ (TH1/17), and IFN-gIL-17þ (Th17) within the CD3þCD4þ T cell subset using intracellular cytokine staining. A representative ﬂow chart of one patient 42 days after
HCT is shown. (B and C) Reconstitution of lymphocytes (B) and CD3þCD4/CD3þCD4þ T cells (C) after HCT. Data of patients with no complications (n ¼ 29) are shown
as dot plots (left panels) and columns (right panels). (Left panels) Dots represent cell counts (GPt/L or MPt/L) in one patient at one time point after HCT. Linear
regression curves (trend lines) and R2 values are indicated. (Right panels) Columns show the mean cell counts ( SD) of healthy donors (n ¼ 8) compared with
patients (n ¼ 29) at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not signiﬁcant.
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Student’s t-test (two-sided, unpaired) was used for statistical evaluation.
P < .05 was considered statistically signiﬁcant.RESULTS
Reconstitution of IL-17Ae and IFN-geProducing T Helper
Cells after HCT
To gain novel insights into the reconstitution of IL-17e
and IFN-geproducing T helper cells after HCT, we used
surface staining for CD3 and CD4 followed by intracellular
cytokine staining for IFN-g and IL-17 in PBMCs (Figure 1A). T
helper cells producing both IFN-g and IL-17 (IFN-gþIL-17þ)
were termed Th1/17 cells, T helper cells producing only either
cytokine alone were indicated as Th17 cells (IFN-gIL-17þ) orTh1 cells (IFN-gþIL-17), and T helper cells producing none of
these cytokines (IFN-gIL-17) were termed non-Th1/17 cells
(Figure 1A). Patients were analyzed once in the ﬁrst month
(days 0-30), second month (days 31-60), and during late
engraftment (days 61-110) after HCT. Figures 1 and 2 show
the data of 29 patients with no relevant complications (no
acute GVHD, bacterial infection, viral reactivation) and no
additional immunosuppressive agents (no ATG or
prednisolone).
Total lymphocyte counts signiﬁcantly increased between
the ﬁrst month (mean  SD, 0.68  0.45 GPt/L) and the
second month (mean  SD, 1.16  0.95 GPt/L) after HCT
(P ¼ .00086; Figure 1B). In late engraftment, no further
increase was detected (mean  SD, 1.20  0.73 GPt/L;
Figure 2. Reconstitution of IFN-ge and IL-17eproducing T helper cells after HCT. CD3þCD4þ T cells were quantiﬁed according to their production of IFN-g and IL-17
(Figure 1A). Data of patients with no complications (n ¼ 29) are shown as dot plots (left panels) and columns (right panels). (Left panels) Dots represent cell count
(KPt/L) in one patient at one time point after HCT. Linear regression curves (trend lines) and R2 values are indicated. (Right panels) Columns show the mean cell
counts ( SD) of healthy donors (n ¼ 8) compared with patients (n ¼ 29) at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not signiﬁcant.
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donors (mean  SD, 2.35  0.78 GPt/L), patients displayed
signiﬁcantly lower numbers of lymphocytes in the periph-
eral blood (Figure 1B), documenting that lymphocytes do
not reconstitute to normal levels within the ﬁrst 110 days
after HCT.
Within the CD3þ T lymphocyte compartment, total
numbers of both CD3þCD4 and CD3þCD4þ T cells were
signiﬁcantly lower in patients in the ﬁrst month after HCT
compared with healthy donors (Figure 1C). When depicting
the reconstitution over time, linear regression curves show
that noneT helper (CD3þCD4) cells expanded, whereas
CD3þCD4þ T cells did not expand signiﬁcantly after the ﬁrst
month after HCT (Figure 1C).
CD3þCD4þ T cells were further dissected according to
their production of IFN-g and IL-17 into Th1, Th1/17, Th17,
and non-Th1/17 cells (Figures 1A and 2). In the ﬁrst monthafter HCT, absolute counts of all T helper cell subtypes were
lower in patients when compared with healthy donors
(Figure 2). After the ﬁrst month, only Th1 cells showed
a signiﬁcant increase in absolute counts (Figure 2),
whereas no signiﬁcant increase was observed for Th17 and
Th1/17 cells.
In healthy donors, the mean percentage ( SD) of Th1,
Th1/17, and Th17 cells within the CD3þCD4þ T helper cell
compartment was, respectively, 10.36%  4.89%, .65%  .41%,
and .15%  .084% (Figure S1). In patients, these percentages
did not signiﬁcantly change in the different time periods
after HCT (Figure S1). Th1 cells were an exception, showing
a slight but signiﬁcant increase of their percentage with
increasing time after HCT.
When comparing reconstitution of Th1, Th1/17, and Th17
cells in patients with no relevant complications receiving
MAC versus RIC conditioning, no major differences were
F. Bahr et al. / Biol Blood Marrow Transplant 19 (2013) 357e365 361found, except for signiﬁcantly higher Th1 cell counts in the
third month in MAC-conditioned patients (RIC patients
[mean  SD], 2.89  104  3.02  104 vs MAC patients
[mean  SD], 6.39  104  7.42  104; P ¼ .039) and elevated
Th1/17 cell counts in RIC-conditioned patients in the ﬁrst
month (RIC patients [mean  SD], 591.4  500.5 vs MAC
patients [mean  SD], 307.8  205.4; P ¼ .047; Figure S2). In
conclusion, these data document that Th1, Th1/17, and Th17
cells are detectable but do not reconstitute to normal levels
within the ﬁrst 3 months after HCT.Effect of ATG on T Helper Cell Reconstitution
ATG in the conditioning regimen has been a common
strategy to prevent GVHD for decades [24]. The effects of ATG
on the lymphocyte compartment include in vivo T cell
depletion via complement-dependent lysis and apoptosis
[24]. The effect of ATG on IL-17eproducing Tcells has also not
been investigated so far. In our study cohort, 11 assessable
patients received ATG as GVHD prophylaxis in the condi-
tioning regimen.
Patients with ATG displayed signiﬁcantly reduced
numbers of lymphocytes in the peripheral blood compared
with time-matched control subjects in the ﬁrst (mean
decrease, 58.6%; P ¼ .00075) and second month after HCT
(mean decrease, 55.2%; P ¼ .0072). However, as predicted by
the half-life of ATG, the effect of ATG on lymphocyte counts
was not signiﬁcant at later time points after allogeneic HCT
(mean decrease, 9.2%; P¼ .59), indicating that ATG-mediated
lymphocyte depletion occurs mostly in the ﬁrst 2 months
after HCT (Figure 3A).
In patients receiving ATG, both CD3þCD4þ T helper and
CD3þCD4 noneT helper cells were suppressed in total
numbers in the peripheral blood (Figure 3B). However, our
data show a longer suppression of CD3þCD4þ T helper cells
(mean decrease: ﬁrst month, 89.9%; second month, 83.8%;
late engraftment, 73.3%; P < .0001) compared with
CD3þCD4 noneT helper cells (mean decrease: ﬁrst month,
58.5%, P ¼ .017; second month, 80.6%, P < .0001; late
engraftment, 10.2%, P ¼ .74). In particular, after the second
month, only CD3þCD4þ T cells remained suppressed by ATG,
whereas CD3þCD4 noneT helper cells reconstituted to
normal levels (Figure 3B). When CD3þCD4þ T cells were
subdivided according to IFN-g and IL-17 production, we
discovered that non-Th1/17 cells (CD3þCD4þ T cells
producing no IFN-g or IL-17) showed the most prominent
reduction in patients receiving ATG (mean decrease: ﬁrst
month, 90.4%; second month, 85.8%; late engraftment,
82.3%; P < .0001, respectively).
Th17 cells were also signiﬁcantly suppressed in patients
receiving ATG comparedwith time-matched control subjects
(mean decrease: ﬁrstmonth, 75.4%, P¼ .0049; secondmonth,
76.7%, P ¼ .0002; late engraftment, 60%, P ¼ .0011). Th1/17
cells were also suppressed inpatientswith ATG, although this
reduction was less prominent and only reached borderline
signiﬁcance in the second month and no signiﬁcance in the
third month after HCT (mean decrease: ﬁrst month, 67.3%,
P ¼ .012; second month, 46.8%, P ¼ .054; late engraftment,
10.9%, P ¼ .69). Finally, Th1 cells were not signiﬁcantly
reduced in patients receiving ATG compared with time-
matched control subjects (mean decrease of Th1 cells in
ATG-treated patients: ﬁrst month, 81.8%, P ¼ .34; second
month, 53.6%, P ¼ .21; late engraftment, 9.5%, P ¼ .8), indi-
cating that the suppressive effect of ATG is less pronounced
on Th1 cells, compared with Th17 and Th1/17 cells.Surprisingly, although total counts were lower, the
percentages of all IFN-gþe and IL-17eproducingThelper cells
(Th1, Th17, and Th1/17) within the CD3þCD4þ T cell pop-
ulationwere signiﬁcantly increased in patients receiving ATG
compared with time-matched control subjects (Figure S3).
This was especially observed in the second and third month
after HCT. Th1 cells showed the most signiﬁcant increase
(Figure S3). This shift toward higher percentages of Th1, Th1/
17, and TH17 cells was most likely due to a preferential
depletionof non-Th1/Th17 cells byATGas shown in Figure 3C.
In summary, these data show that Th17 and Th1/17 cells,
but not Th1 cells, were signiﬁcantly suppressed in patients
receiving ATG.
IL-17Ae and IFN-geProducing T Helper Cells in Acute
GVHD
To investigate a possible role of Th17 cells in the human
GvHD, we quantiﬁed Th17 and TH1/17 cells in 6 evaluable
patients with acute GvHD grade I (gut GvHD n¼ 1, skin GvHD
n ¼ 5; median time: 51 days after HCT; Figure 4A-C) and 8
evaluable patients with acute GvHD grade II-IV (gut GvHD
n ¼ 4, skin GvHD n ¼ 4; median time: 33 days after HCT;
Figure 4D-F). Blood samples were taken before the applica-
tion of prednisolone. In short, there was a tendency toward
increased counts of Th1 and Th1/17 cells in the peripheral
blood of patients with severe GVHD (Figure 4F). These
changes were not statistically different compared with time-
matched control subjects. We cannot, however exclude that
a larger sample size might result in signiﬁcant differences (in
particular for Th1 and Th1/17 cell counts) between the GVHD
cohort versus respective control subjects.
Modulation of T Helper Cells during CMV Reactivation
and Bacterial Infection
HCT also includes the risk of opportunistic bacterial and
viral infections. Th17 cells physiologically initiate and
mediate adaptive immune responses against pathogens [25].
The role of Th17 cells in immune responses toward patho-
gens after HCT remains to be deﬁned.
CMV is the most common viral reactivation after HCT and
occurred in 7 assessable patients of our study cohort after
amedian time of 63 days afterHCT. As shown in Figure 5A,we
detected higher counts of lymphocytes in the peripheral
blood of patients with CMV reactivation, compared with
time-matched control subjects (mean increase, 120.7%,
P ¼ .0051; Figure 5A). Surprisingly, only CD3þCD4 (noneT
helper) cells expanded in response to CMV reactivation
(mean increase, 300.1%, P < .0001; Figure 5B), whereas total
countsof CD3þCD4þTcells didnot change signiﬁcantly (mean
increase, 21.3%, P ¼ .88; Figure 5B). However, within the
CD3þCD4þ T cell compartment, there was a signiﬁcant shift
from non-Th1/17 cells toward Th1, Th17, and Th1/17 cells.
Total counts of these cells were signiﬁcantly increased in the
peripheral blood, andTh1cells showed the strongest increase,
whereas non-Th1/17 cells did not signiﬁcantly increase in
numbers (Figure 5C). These data show that Th1, Th1/17, and
Th17 cellswere up-regulated in response toCMVreactivation.
Bacterial infection occurred in 15 assessable patients
within the ﬁrst month after HCT (median time, 15 days after
HCT). Compared with time-matched control subjects, no
signiﬁcant changes were found in the lymphocyte and T
helper cell compartment (Figure 5, D-F). Overall, there was
a tendency of lower counts for Th1, Th1/17, and Th17 cells in
patients with early bacterial infection, but these ﬁndings did
not reach statistical signiﬁcance (Figure 5F).
Figure 3. Effect of ATG on the reconstitution of lymphocytes (A), CD3þCD4/CD3þCD4þ T cells (B), and Th1, Th17, and Th1/17 cells (C). Data of patients with ATG
(n ¼ 11) versus time-matched control subjects (n ¼ 29) are shown. Mean quantity ( SD) of lymphocytes, CD3þCD4þ/CD3þCD4 T cells, and T helper cells are
indicated in GPt/L, MPt/L, or KPt/L at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not signiﬁcant.
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Considering their potential role in acute GVHD, we
monitored the reconstitution of IL-17eproducing T helper
cells in a large cohort of patients after allogeneic HCT. Patients
with no ATG in the conditioning regimen showed a rapid
increment of IL-17eproducing T helper cells (Th17 and Th1/
17 cells) in the ﬁrst month. However, after the ﬁrst month,
these cells did not further expand or reconstitute to normal
levels compared with healthy donors. Th1 cells, but not Th1/
17 and Th17 cells expanded after the ﬁrst month after HCT. Apossible explanation for the partial reconstitution of
Th17 and Th1/17 cells might be cyclosporine or tacrolimus,
which had been administered to all patients and are
known to inhibit T cell proliferation via interference with
calcineurin-induced IL-2 transcription [26] and to suppress
IL-17 production in T cells in vitro [27]. It was discovered that
human Th17 cells are susceptible for Th1 differentiation
in vivo [21-23]. Therefore, the expansion of Th1 cells
observed in this study could be due to differentiation of
IL-17eproducing T helper cells into Th1 cells.
Figure 4. Impact of acute GVHD grade I (A-C) and II-IV (D-F) on the frequency of lymphocytes, CD3þCD4/CD3þCD4þ T cells, and Th1, Th17, and Th1/17 cells. Data of
patients with acute GVHD grade I (A-C, n ¼ 6) and grade II-IV (D-F, n ¼ 8) versus time-matched control subjects (n ¼ 22 and n ¼ 24, respectively) are shown. Mean
quantity ( SD) of lymphocytes (A and D), CD3þCD4þ/CD3þCD4 T cells (B and E), and IL-17/IFN-geproducing T helper cells (C and F) are indicated in GPt/L, MPt/L, or
KPt/L. n.s., not signiﬁcant.
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effects on transplantation outcome by reducing the
frequency of acute and chronic GVHD [3,4]. In this study, the
usage of ATG in the conditioning regimen was signiﬁcantly
associated with the suppression of Th17 cells for at least 3
months after HCT. Our results indicate that depletion of Th17
cells might be a potential mechanism of ATG-mediated
GVHD prevention. Interestingly, ATG-mediated depletion of
Th17, Th1/17, and Th1 cells was less pronounced compared
with the depletion of non-Th1/17 cells. Possible mechanisms
could include the ability of IL-17e and IFN-geproducing T
cells to reconstitute/proliferate faster after ATG mediatedin vivo depletion or a higher intrinsic resistance toward
complement-mediated lysis compared with non-Th1/17
cells. Overall, CD3þCD4þ T cells were depleted more efﬁ-
ciently compared with CD3þCD4 T cells, which might be
due to the fact that ATG is a polyclonal antiserum generated
against CD4-expressing Jurkat lymphoblastic T cells.
In this study,wedeterminedabsolute counts of IFN-ge and
IL-17eproducing T cells in patients with acute GVHD and did
not observe signiﬁcant changes in their quantity compared
with time-matched control subjects. Previous studies in
patients with acute GVHD obtained controversial results on
the association of Th17 cell quantity in the peripheral blood
Figure 5. Modulation of lymphocyte, CD3þCD4þ/CD3þCD4 T cells, and Th1, Th17, and Th1/17 cell counts by CMV reactivation (A-C) and early bacterial infection
(D-F). Data of patients with CMV reactivation (A-C, n ¼ 7) and early bacterial infection (D-F, n ¼ 15) versus time-matched control subjects (n ¼ 21 and n ¼ 20,
respectively) are shown. Mean quantity ( SD) of lymphocytes (A and D), CD3þCD4þ/CD3þCD4 T cells (B and E), and IL-17/IFN-geproducing T helper cells (C and F)
are indicated in GPt/L, MPt/L, or KPt/L. *P < .05, **P < .01, ***P < .001, n.s., not signiﬁcant.
F. Bahr et al. / Biol Blood Marrow Transplant 19 (2013) 357e365364and the onset of acute GVHD. In patients with acute GVHD,
Dlubek et al. [20] found decreased Th17 levels, whereas
Dander et al. [16] found increased Th17 proportions, and,
ﬁnally, Broady et al. [18] and Ratajczak et al. [19] found no
differences in the percentages of Th17 cells in the peripheral
blood of GVHDpatients comparedwith time-matched control
subjects. However, in contrast to previous studies, this study
determined total counts (andnot only thepercentages) of Th1,
Th1/17, and Th17 cells in the peripheral blood.
Changes in the percentage of Th17 cells may simply
reﬂect expansion or decrease of T cell populations other thanTh17. For example, our study shows that ATG increases the
percentage (Figure S2) but decreases total counts (Figure 3C)
of Th17 cells. In addition, none of the previous studies
considered CMV reactivation as a possible parameter inﬂu-
encing Th17 cell levels. In our patient cohort, CMV reac-
tivation triggered a signiﬁcant expansion of Th17, Th1, and
Th1/17 cells. Our study indicates a function of Th17 cells in
anti-CMV immune responses. Because CMV reactivation
occurs signiﬁcantly more often in patients with acute GVHD
[28], the difference in Th17 percentages between patients
with acute GVHD and no GVHD in previous studies might
F. Bahr et al. / Biol Blood Marrow Transplant 19 (2013) 357e365 365therefore be due to a higher proportion of patients with CMV
reactivation in the GVHD cohorts [16,18-20]. Finally, previous
studies did not consider ATG as a parameter, inﬂuencing
Th17 cell levels.
Our study shows that about 20% of IL-17eproducing T
helper cells coproduce IFN-g after HCT. This “Th1/17”
phenotypewas shown to have the ability to differentiate into
the Th1 phenotype [21-23] andmight therefore contribute to
Th1 responses, including alloreactivity after HCT. Hence, IL-
17eproducing T cells might contribute to GVHD without
showing numeral expansion but via differentiation into the
Th1 phenotype. Therefore, our ﬁndings do not rule out a role
of Th17 cell population in the pathogenesis of acute GVHD.
This is further supported by the fact that all histologic studies
so far detected IL-17eproducing T cells in the target organs of
GVHD, indicating extravasation and migration of Th17 cells
into these tissues [16-19]. Inhibition of Th17 cell function
using ustekinumab (which binds to p40 subunit of IL-12 and
IL-23) has shown efﬁcacy and safety in patients with Th17-
associated autoimmune diseases (eg, psoriasis and Crohn’s
disease) [29]. Only recently was it demonstrated that uste-
kinumab can successfully induce complete remission of
steroid-refractory GVHD in a patient after HCT [30], indi-
cating that agents targeted against Th17 cell function hold
promise for GVHD prevention or treatment.
However, modulation of Th17 cell responses also carries
potential risks, and therefore caution is required in clinical
trials. Data from Yi et al. indicate that absence of donor Th17
cells can exacerbate GVHD [14]. In addition, our data indicate
a function of Th17 cells in immune responses toward
opportunistic infectious agents, in particular CMV. Depletion
of Th17 cells might therefore lead to increased incidence or
severity of CMV reactivation or other opportunistic infec-
tions. Of note, the patient in whom ustekinumab induced
complete remission of GVHD died from an infectious
complication [30].
Together, we studied the reconstitution kinetics of
IL-17eproducing T cells and their association with compli-
cations. Further studies are required to deﬁne the role of
IL-17eproducing T cells in alloreactivity and immune
responses toward pathogens after HCT to use themodulation
of these cells to improve transplantation outcomes.
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